NASDAQ · XGN

Exagen Inc.

$4.40 -$0.28 (-5.98%) 1D Market open

Key Metrics

$113.07M
Market cap
P/E · TTM
$68.38M
Revenue · TTM
−$20.17M
Net income
EPS · TTM $-1.09
Dividend yield
Free cash flow −$14.13M
Beta · 1Y 1.84
EBITDA · TTM −$11.82M
Gross margin 58.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 11
    The stock moved +34.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 11
  • Mar 31
    The stock moved +13.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 31
  • Mar 30
    From its Jan 29 high, the share price fell 33%.

    Peak close $3.95 on Jan 29; trough close $2.65 on Mar 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -33%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$113.07M
Enterprise value$114.43M
Shares outstanding24.2M
52-wk range$2.59 – $12.23
Avg volume · 20D118.6K
Net cash −$1.36M
Book value / share$0.78
IndustryServices-Medical Laboratories
ExchangeNASDAQ
About Exagen Inc.
IPO dateSep 19, 2019
Employees220

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.65
P/FCF
EV/EBITDA
EV/Sales1.67
Graham №

Profitability

Gross 58.3%
Operating -20.6%
Net -29.5%
FCF -20.7%
ROE / ROIC -168.2% · —

Financial Health

Current ratio3.47
Quick ratio
Debt / equity1.58
Debt / EBITDA -1.94
Net cash −$1.36M
Working capital$31.02M

Cash Flow · TTM

Operating CF −$13.37M
Capex −$756.00K
Free cash flow −$14.13M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-5.6
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings